Implications of MGMT methylation status in pituitary adenoma

Pathology Research and Practice

Volumn 210, Issue 7, 2014, Pages 407-411

  Arya, Sneha ^a   Majaid, M A ^a   Shwetha, S D ^a   Sravani, K ^a   Arivazhagan, A ^a   Sampath, S ^a   Santosh, V ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

Adjuvant therapy; Methylation specific PCR; MGMT immunohistochemistry; MGMT methylation; Pituitary adenoma; Temozolomide

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TUMOR SUPPRESSOR PROTEIN;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA METHYLATION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; MALE; MGMT GENE; MIDDLE AGED; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; SCHOOL CHILD; TUMOR RECURRENCE; YOUNG ADULT; ADENOMA; GENETICS; HYPOPHYSIS TUMOR; INDIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOMA; ADOLESCENT; ADULT; AGED; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INDIA; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84901497752     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2014.02.010     Document Type: Article

References (22)

1. Bello M.J., De Campos J.M., Isla A., Casartelli C., Rey J.A. Promoter CpG methylation of multiple genes in pituitary adenomas: frequent involvement of caspase-8. Oncol. Rep. 2006, 15:443-448.
2. Bush Z.M., Longtine J.A., Cunningham T., Schiff D., Jane J.A., Vance M.L., Thorner M.O., Laws E.R., Lopes M.B. Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression. J. Clin. Endocrinol. Metab. 2010, 95:E280-E290.
3. Chacko G., Chacko A.G., Kovacs K., Scheithauer B.W., Mani S., Muliyil J.P., Seshadri M.S. The clinical significance of MIB-1 labeling index in pituitary adenomas. Pituitary 2010, 13:337-344.
4. Comtois R., Beauregard H., Somma M., Serri O., Aris-Jilwan N., Hardy J. The clinical and endocrine outcome to trans-sphenoidal microsurgery of nonsecreting pituitary adenomas. Cancer 1991, 68:860-866.
5. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999, 59:793-797.
6. Ferrante E., Ferraroni M., Castrignano T., Menicatti L., Anagni M., Reimondo G., Del Monte P., Bernasconi D., Loli P., Faustini-Fustini M., Borretta G., Terzolo M., Losa M., Morabito A., Spada A., Beck-Peccoz P., Lania A.G. Non-functioning pituitary adenoma database: a useful resource to improve the clinical management of pituitary tumors. Eur. J. Endocrinol. 2006, 155:823-829.
7. Gandour-Edwards R., Kapadia S.B., Janecka I.P., Martinez A.J., Barnes L. Biologic markers of invasive pituitary adenomas involving the sphenoid sinus. Mod. Pathol. 1995, 8:160-164.
8. Hegi M.E., Diserens A.C., Gorlia T., Hamou M.F., de Tribolet N., Weller M., Kros J.M., Hainfellner J.A., Mason W., Mariani L., Bromberg J.E., Hau P., Mirimanoff R.O., Cairncross J.G., Janzer R.C., Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 2005, 352:997-1003.
9. 6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J. Clin. Oncol. 2008, 26:4189-4199.
10. Kovacs K., Scheithauer B.W., Lombardero M., McLendon R.E., Syro L.V., Uribe H., Ortiz L.D., Penagos L.C. MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol. 2008, 115:261-262.
11. Kulke M.H., Stuart K., Enzinger P.C., Ryan D.P., Clark J.W., Muzikansky A., Vincitore M., Michelini A., Fuchs C.S. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J. Clin. Oncol. 2006, 24:401-406.
12. Lubke D., Saeger W., Ludecke D.K. Proliferation markers and EGF in ACTH-secreting adenomas and carcinomas of the pituitary. Endocr. Pathol. 1995, 6:45-55.
13. 6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin. Endocrinol. (Oxf.) 2009, 71:226-233.
14. Mineura K., Yanagisawa T., Watanabe K., Kowada M., Yasui N. Human brain tumor O(6)-methylguanine-DNA methyltransferase mRNA and its significance as an indicator of selective chloroethylnitrosourea chemotherapy. Int. J. Cancer 1996, 69:420-425.
15. Oliveira M.C., Marroni C.P., Pizarro C.B., Pereira-Lima J.F., Barbosa-Coutinho L.M., Ferreira N.P. Expression of p53 protein in pituitary adenomas. Braz. J. Med. Biol. Res. 2002, 35:561-565.
16. Raverot G., Sturm N., de Fraipont F., Muller M., Salenave S., Caron P., Chabre O., Chanson P., Cortet-Rudelli C., Assaker R., Dufour H., Gaillard S., Francois P., Jouanneau E., Passagia J.G., Bernier M., Cornelius A., Figarella-Branger D., Trouillas J., Borson-Chazot F., Brue T. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J. Clin. Endocrinol. Metab. 2010, 95:4592-4599.
17. Salehi F., Scheithauer B.W., Kros J.M., Lau Q., Fealey M., Erickson D., Kovacs K., Horvath E., Lloyd R.V. MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas. J. Neurooncol. 2011, 104:647-657.
18. Stupp R., Hegi M.E., Mason W.P., van den Bent M.J., Taphoorn M.J., Janzer R.C., Ludwin S.K., Allgeier A., Fisher B., Belanger K., Hau P., Brandes A.A., Gijtenbeek J., Marosi C., Vecht C.J., Mokhtari K., Wesseling P., Villa S., Eisenhauer E., Gorlia T., Weller M., Lacombe D., Cairncross J.G., Mirimanoff R.O. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009, 10:459-466. European Organisation for R, Treatment of Cancer Brain T, Radiation Oncology G National Cancer Institute of Canada Clinical Trials G.
19. Suliman M., Royds J., Cullen D., Timperley W., Powell T., Battersby R., Jones T.H. Mdm2 and the p53 pathway in human pituitary adenomas. Clin. Endocrinol. (Oxf.) 2001, 54:317-325.
20. Syro L.V., Uribe H., Penagos L.C., Ortiz L.D., Fadul C.E., Horvath E., Kovacs K. Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm. Clin. Endocrinol. (Oxf.) 2006, 65:552-553.
21. Tanaka Y., Hongo K., Tada T., Sakai K., Kakizawa Y., Kobayashi S. Growth pattern and rate in residual nonfunctioning pituitary adenomas: correlations among tumor volume doubling time, patient age, and MIB-1 index. J. Neurosurg. 2003, 98:359-365.
22. Thapar K., Kovacs K., Scheithauer B.W., Stefaneanu L., Horvath E., Pernicone P.J., Murray D., Laws E.R. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 1996, 38:99-106. discussion 106-7.